Abies Alba Leafy Twig Bos Taurus Gallstone Calcium
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Abies Alba Leafy Twig Bos Taurus Gallstone Calcium
- Multi-Ingredient Complex (24 Components): Insufficient Data for Repurposing Evaluation
Multi-Ingredient Complex (24 Components): Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This candidate is a 24-component multi-ingredient formulation comprising calcium salts, botanical extracts, animal-derived substances, and homeopathic constituents, with no established approved indication on record. The TxGNN model returned no predicted indications for this entry, likely due to the absence of a single mappable DrugBank identifier and the highly heterogeneous ingredient list. As a result, no clinical trial or literature evidence can be linked to a repurposing direction at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indication on record) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The TxGNN model operates by mapping a drug’s DrugBank identifier into a biomedical knowledge graph and traversing disease–gene–protein relationships to surface repurposing candidates.
This entry has no DrugBank ID (drugbank_id: null), which means no node exists in the knowledge graph to serve as a starting point for traversal.
The ingredient list contains 24 heterogeneous substances — including inorganic calcium salts (e.g., calcium arsenate, calcium fluoride), homeopathic botanicals (e.g., Calendula officinalis, Urtica urens, Hamamelis virginiana), and animal-derived components (e.g., bovine gallstone, porcine parathyroid gland). Such multi-ingredient homeopathic complexes are typically not registered as discrete entities in DrugBank or standard pharmacological databases, making knowledge-graph-based prediction technically infeasible without prior ingredient decomposition and individual mapping.
US Market Information
No US NDA or regulatory authorization was found for this formulation.
Safety Considerations
Please refer to the package insert for safety information.
Note: Package insert data (warnings, contraindications) could not be retrieved (Data Gap DG001 — Blocking severity). Drug interaction screening returned no results. Safety evaluation cannot be completed without resolving this gap.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model produced no repurposing candidates for this entry because the formulation lacks a DrugBank ID and is not representable as a single node in the knowledge graph; without a prediction to evaluate, there is no repurposing direction to assess.
To proceed, the following is needed:
- Ingredient decomposition — Determine whether any single active ingredient (e.g., Vitamin D, Calcium, Cholesterol) can be evaluated independently using TxGNN; resubmit each as a separate candidate.
- DrugBank mapping — Identify DrugBank IDs for individual pharmacologically active components before re-running the prediction pipeline.
- Clarify therapeutic intent — Establish the intended or historical use of this formulation (homeopathic, naturopathic supplement, etc.) to determine whether knowledge-graph-based repurposing is the appropriate evaluation framework.
- Retrieve package insert data — Resolve Data Gap DG001 (Blocking) by downloading and parsing the TFDA product monograph PDF to obtain warnings, contraindications, and approved indications.
- MOA documentation — Resolve Data Gap DG002 (High) by querying DrugBank for mechanism-of-action data on individual identifiable components.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.